$RGPX
REGENEREX PHARMA, INC.

2023 Q3 Form 10-Q Financial Statement

#000147237523000123 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2023 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $160.2K
YoY Change
% of Gross Profit
Research & Development $2.400M
YoY Change
% of Gross Profit
Depreciation & Amortization $831.00
YoY Change -22.41%
% of Gross Profit
Operating Expenses $2.786M $160.2K
YoY Change 12855.37% 826.66%
Operating Profit -$2.786M -$160.2K
YoY Change 12855.37% 826.66%
Interest Expense $19.80K $18.51K
YoY Change 19.23% 19.26%
% of Operating Profit
Other Income/Expense, Net -$15.53K -$25.40K
YoY Change -606.06% 329.14%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$2.801M -$185.6K
YoY Change 15095.54% 699.75%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 277.4M shares 277.1M shares 277.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q3 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $6.080K $67.75K $1.135K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $13.25K $23.30K
Receivables
Other Receivables
Total Short-Term Assets $19.33K $91.05K $1.135K
YoY Change 517.77% 2082.5% -85.63%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $913.3K $948.6K $5.404K
YoY Change 16116.51% 14826.04% -27.23%
TOTAL ASSETS
Total Short-Term Assets $19.33K $91.05K $1.135K
Total Long-Term Assets $913.3K $948.6K $5.404K
Total Assets $932.6K $1.040M $6.539K
YoY Change 10545.41% 9775.6% -57.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $89.84K $96.50K $75.15K
YoY Change 35.73% 67.86% 19.23%
Accrued Expenses $82.03K $76.97K $125.8K
YoY Change -21.32% -13.35% 37.22%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.338M $801.7K $776.8K
YoY Change 327.71% 7.34% 17.61%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.338M $801.7K $776.8K
Total Long-Term Liabilities $0.00
Total Liabilities $4.566M $2.124M $1.129M
YoY Change 340.72% 108.33% 12.84%
SHAREHOLDERS EQUITY
Retained Earnings -$5.059M -$2.258M -$2.072M
YoY Change 155.98% 15.31% 7.1%
Common Stock $277.9K $277.3K $277.1K
YoY Change 0.29% 0.08% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.633M -$1.084M -$1.123M
YoY Change
Total Liabilities & Shareholders Equity $932.6K $1.040M $6.539K
YoY Change 10545.41% 9775.6% -57.32%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$2.801M -$185.6K
YoY Change 15095.54% 699.75%
Depreciation, Depletion And Amortization $831.00
YoY Change -22.41%
Cash From Operating Activities -$121.2K
YoY Change 245.72%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$3.629K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $191.5K
YoY Change 461.54%
NET CHANGE
Cash From Operating Activities -$121.2K
Cash From Investing Activities -$3.629K
Cash From Financing Activities $191.5K
Net Change In Cash $66.62K
YoY Change -6982.13%
FREE CASH FLOW
Cash From Operating Activities -$121.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 dei Entity Central Index Key
EntityCentralIndexKey
0001357878
CY2023Q2 dei Amendment Flag
AmendmentFlag
false
CY2023Q2 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q2 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q2 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
usd
CY2023Q1 us-gaap Notes Payable
NotesPayable
usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
usd
CY2022Q2 us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
usd
CY2022Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2023Q2 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
usd
CY2022Q2 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
usd
CY2023Q2 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2022Q2 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2023Q2 us-gaap Interest Paid
InterestPaid
usd
CY2022Q2 us-gaap Interest Paid
InterestPaid
usd
CY2022Q2 RGPX Operating Leases Rou Asset And Liabilities
OperatingLeasesRouAssetAndLiabilities
usd
CY2023Q2 us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
usd
CY2023Q2 dei Document Type
DocumentType
10-Q
CY2023Q2 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q2 dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023Q2 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q2 dei Entity File Number
EntityFileNumber
000-53230
CY2023Q2 dei Entity Registrant Name
EntityRegistrantName
REGENEREX PHARMA, INC.
CY2023Q2 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q2 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0479983
CY2023Q2 dei Entity Address Address Line1
EntityAddressAddressLine1
5348 Vegas Drive #177
CY2023Q2 dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
CY2023Q2 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2023Q2 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89108
CY2023Q2 dei City Area Code
CityAreaCode
(877)
CY2023Q2 dei Local Phone Number
LocalPhoneNumber
761-7479
CY2023Q2 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q2 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q2 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q2 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q2 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q2 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q2 dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
277437660 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67754 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1135 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
23300 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
91054 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
1135 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
27112 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
26397 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3488 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4203 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
313 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
197 usd
CY2023Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
4714 usd
CY2023Q1 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
1201 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
940348 usd
CY2023Q2 us-gaap Assets
Assets
1039604 usd
CY2023Q1 us-gaap Assets
Assets
6539 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
96504 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
75145 usd
CY2023Q2 RGPX Related Party Advances
RelatedPartyAdvances
1685 usd
CY2023Q1 RGPX Related Party Advances
RelatedPartyAdvances
131887 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
221192 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
221192 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
76973 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
125787 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
268489 usd
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
222771 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
136883 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
801726 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
776782 usd
CY2023Q2 RGPX Notes Payable Shareholder
NotesPayableShareholder
295769 usd
CY2023Q1 RGPX Notes Payable Shareholder
NotesPayableShareholder
314704 usd
CY2023Q2 RGPX Notes Payable Related Parties
NotesPayableRelatedParties
38000 usd
CY2023Q1 RGPX Notes Payable Related Parties
NotesPayableRelatedParties
38000 usd
CY2023Q2 us-gaap Notes Payable
NotesPayable
184232 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
803845 usd
CY2023Q2 us-gaap Liabilities
Liabilities
2123572 usd
CY2023Q1 us-gaap Liabilities
Liabilities
1129486 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
675000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
675000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
277332660 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
277332660 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
277112660 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
277112660 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
277333 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
277113 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
896297 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
671963 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2257598 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2072023 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1083968 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1122947 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1039604 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6539 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
157174 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17285 usd
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
160174 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
17285 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-160174 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17285 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
18506 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
15518 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-6895 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
9599 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25401 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5919 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-185575 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-23204 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
277156286 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127112660 shares
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-185575 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-23204 usd
CY2023Q2 us-gaap Depreciation
Depreciation
831 usd
CY2022Q2 us-gaap Depreciation
Depreciation
1071 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
34554 usd
CY2023Q2 us-gaap Related Party Transaction Rate
RelatedPartyTransactionRate
0.10 pure
CY2022Q2 RGPX Related Party Advances
RelatedPartyAdvances
100 usd
CY2023Q2 RGPX Related Party Advances
RelatedPartyAdvances
1685 usd
CY2023Q1 RGPX Related Party Advances
RelatedPartyAdvances
131887 usd
CY2023Q2 RGPX Notes Payable Related Parties
NotesPayableRelatedParties
38000 usd
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
981 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
380 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-6895 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
9599 usd
CY2023Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-23300 usd
CY2022Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2756 usd
CY2023Q2 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
44978 usd
CY2022Q2 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6092 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-121237 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35068 usd
CY2023Q2 us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
3629 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3629 usd
CY2023Q2 us-gaap Proceeds From Collection Of Longterm Loans To Related Parties
ProceedsFromCollectionOfLongtermLoansToRelatedParties
1485 usd
CY2022Q2 us-gaap Proceeds From Collection Of Longterm Loans To Related Parties
ProceedsFromCollectionOfLongtermLoansToRelatedParties
100 usd
CY2022Q2 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
34000 usd
CY2023Q2 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
190000 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
191485 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34100 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
66619 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-968 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1135 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2640 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67754 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1672 usd
CY2023Q2 RGPX Accrued Interest Converted Into Note Payable To Shareholder
AccruedInterestConvertedIntoNotePayableToShareholder
72996 usd
CY2022Q2 RGPX Accrued Interest Converted Into Note Payable To Shareholder
AccruedInterestConvertedIntoNotePayableToShareholder
1435 usd
CY2023Q2 RGPX Operating Leases Rou Asset And Liabilities
OperatingLeasesRouAssetAndLiabilities
953535 usd
CY2022Q2 us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
150000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-985617 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-23204 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1008821 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1122947 usd
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
190000 shares
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
190000 usd
CY2023Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
30000 shares
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
34554 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-185575 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1083968 usd
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
0 usd
CY2023Q1 us-gaap Notes And Loans Payable
NotesAndLoansPayable
537475 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Arrangements Description
BusinessCombinationContingentConsiderationArrangementsDescription
and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months.
CY2023Q2 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin: 0px; font-size: 10pt"><b>NOTE 1 – NATURE OF OPERATIONS</b></p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on November 18, 2005.</p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15<sup>th</sup> of the following month, for a period of 60 months.  The Company received all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds.  These unique products strategically position the Company to enter the wound treatment market in the U.S.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Management has decided to focus on this new business development.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Risks and Uncertainties</i></p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position, and cash flows.</p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The Company has a lack of revenue history and has had a limited history of operations.  No revenue has historically been derived from the assets purchased.  Regenerex can give no assurance of success or profitability to the Company’s investors.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The wound care healing space is well suited for Home Care service providers that are funded by the US Government.  Strategic planning and development will be performed internally by the Company.</p> <p style="margin: 0px; font-size: 10pt"> </p>
CY2023Q2 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-11-18
CY2021Q4 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
10000000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2257598 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1083968 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1115000 shares
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2022Q2 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P3Y
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
715 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1071 usd
CY2023Q2 us-gaap Property Plant And Equipment Preproduction Design And Development Costs
PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts
<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Furniture and Computer Equipment</i></p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Furniture and computer equipment are stated at cost, less accumulated depreciation.  Depreciation is computed using the straight-line method over the estimated useful life of three (3) to five (5) years.  Depreciation expense for the three months ended June 30, 2023 and 2022 was $116 and $0.  Significant betterments are capitalized while purchases under $500 are expensed as incurred.</p> <p style="margin: 0px; font-size: 10pt"> </p>
CY2023Q2 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
116 usd
CY2022Q2 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
0 usd
CY2021Q4 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
10000000 usd
CY2023Q2 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
On June 10, 2023, the Company entered into a plant facility lease agreement with a related party commencing June 9, 2023 which expires on June 30, 2028.  Under this agreement, the monthly rental payments are $18,000 throughout the term of the lease excepting the month of June 2023 the rent is $7,920, The Company is working to have the premise certified by the FDA and will pay all related costs.  Until the certification is complete, the monthly rent is reduced by forty (40%) percent to $10,800. Under this agreement, the Company is also leasing the equipment in the plant facility through five (5) annual rent payments of $10,000, which are due on the 15th day of  each June from June 2023 to June 2027.
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
675000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
On June 19, 2023, the Company signed an advisory agreement with a consultant as an advisor for a period of one (1) year.  Agreed compensation is a warrant to purchase up to one hundred twenty thousand (120,000) common shares of the company exercisable at thirty-three ($0.33) cents with a five (5) year option to execute.  The warrants shall be earned on a prorate basis, calculated monthly from July 1, 2023 to June 30, 2024.
CY2023Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.18
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
190000 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
190000 usd
CY2023Q2 us-gaap Temporary Equity Contract Terms
TemporaryEquityContractTerms
Five warrants were issued for each share purchased, for a total of nine hundred fifty thousand (950,000) warrants.  The warrants are exercisable at twenty ($0.20) cents and expire twenty-four (24) months after the date of the purchase agreement.
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1115000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
Subsequent we approved the issuance of one hundred and five thousand (105,000) shares of common stock with a par value of $0.001 for the price one ($1) per share for a total of one hundred five thousand ($105,000) dollars.  Five warrants were issued for each share purchased, for a total of 525,000 warrants.  The warrants are exercisable at twenty ($0.20) cents and expire twenty-four (24) months after the date of the purchase agreements.

Files In Submission

Name View Source Status
0001472375-23-000123-index-headers.html Edgar Link pending
0001472375-23-000123-index.html Edgar Link pending
0001472375-23-000123.txt Edgar Link pending
0001472375-23-000123-xbrl.zip Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ixform10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ixform10q_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
regenerexlogo.gif Edgar Link pending
report.css Edgar Link pending
rgpx-20230630.xsd Edgar Link pending
Show.js Edgar Link pending
rgpx-20230630_cal.xml Edgar Link unprocessable
rgpx-20230630_def.xml Edgar Link unprocessable
rgpx-20230630_lab.xml Edgar Link unprocessable
rgpx-20230630_pre.xml Edgar Link unprocessable